Luo Y, et al. - In patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with octreotide long-acting repeatable (LAR), researchers wanted to find a dependable early indicator of deriving progression-free survival (PFS) benefit. For this investigation, they studied the images of 50 subjects with well-differentiated advanced GEP-NETs treated with LAR octreotide and had baseline and follow-up thoracic, abdominal, and pelvic computed tomography. In advanced GEP-NETs, a 10% reduction in tumor size was an optimal early predictor of response to octreotide LAR. In patients with well-differentiated advanced GEP-NETs, octreotide LAR could significantly lengthen PFS. In GEP-NETs with octreotide, no optimal tumor size-based response criteria were reported.